Daiichi Sankyo (OTCMKTS:DSNKY) Co., Ltd. is a global pharmaceutical company headquartered in Tokyo, Japan, engaged in the research, development, manufacturing and commercialization of innovative prescription medicines. Established through the merger of Daiichi Pharmaceutical Co., Ltd. and Sankyo Co., Ltd. in 2005, the company has built a strong heritage of scientific discovery dating back more than a century. As a publicly traded entity on the Tokyo Stock Exchange and represented in U.S. markets via its ADR (OTCMKTS: DSNKY), Daiichi Sankyo leverages its legacy to address unmet medical needs across a spectrum of therapeutic areas.
The company’s core business activities center on the discovery and development of treatments in oncology, cardiovascular disease, and rare or specialty conditions. In oncology, Daiichi Sankyo is advancing next-generation antibody–drug conjugates and targeted therapies designed to improve patient outcomes in solid tumors. Within cardiovascular care, the company markets oral anticoagulants and angiotensin II receptor blockers, while its hematology pipeline includes innovative agents for anemia management in chronic kidney disease. Beyond these focus areas, the company maintains a diverse portfolio that spans vaccines, antibiotics and supportive care medicines.
Daiichi Sankyo maintains a broad geographic footprint, serving patients and healthcare providers in Japan, North America, Europe and key Asian markets. Its operations encompass research and development sites, manufacturing facilities and affiliate sales organizations that enable local market access and regulatory compliance. The company has forged strategic collaborations with academic institutions and biotechnology partners worldwide, enhancing its capacity to translate scientific breakthroughs into clinical therapies.
Under the leadership of President and Chief Executive Officer Sunao Manabe, Daiichi Sankyo continues to invest heavily in R&D, with a focus on precision medicine and immuno-oncology. The company’s strategic vision emphasizes sustainable growth through innovation, operational excellence and collaboration, positioning it to bring forward a robust pipeline of new therapies that aim to address critical healthcare challenges around the globe.
